

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Miji International Holdings Limited **米技國際控股有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1715)

VOLUNTARY ANNOUNCEMENT **CAPITAL INJECTION AGREEMENT**

This is a voluntary announcement made by Miji International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”).

THE CAPITAL INJECTION AGREEMENT

The board (the “**Board**”) of the directors (the “**Directors**”) of the Company is pleased to announce that on 18 July 2022, 上海米眼波科技有限公司 (Shanghai Miyanbo Technology Co., Ltd.*) (“**Shanghai Miyanbo**”), an indirect wholly-owned subsidiary of the Company entered into a capital injection agreement (the “**Capital Injection Agreement**”) with Mr. Zhang Jun (張軍) (“**Mr. Zhang**”), Ms. Huang Xiaoqiong (黃小琼) (“**Ms. Huang**”) and Mr. Lin Libin (林李斌) (“**Mr. Lin**”) in relation to the capital injection into 廣州螞蟻雲科技有限公司 (Guangzhou Ant Cloud Technology Co., Ltd.*) (“**Guangzhou Ant**”).

As at the date of this announcement, Guangzhou Ant is owned as to 35% by Mr. Zhang, 35% by Ms. Huang and 30% by Mr. Lin, respectively.

Pursuant to the Capital Injection Agreement, Shanghai Miyanbo will inject capital of RMB5,400,000 into Guangzhou Ant. Upon completion of such capital injection, Guangzhou Ant will be owned as to 35% by Shanghai Miyanbo, 22.75% by Mr. Zhang, 22.75% by Ms. Huang and 19.50% by Mr. Lin, respectively.

BACKGROUND OF GUANGZHOU ANT

Guangzhou Ant is a company incorporated in China with limited liability in 2019. Since incorporation, Guangzhou Ant has been focusing on the operation of (i) a technology-based online platform capturing healthcare big data, which can assist entrepreneurs and their research and development teams to transform innovative ideas into healthcare products; and (ii) an e-commerce platform for the trading of healthcare products.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Guangzhou Ant and its ultimate beneficial owners are independent of and not connected with the Company or its connected persons as at the date of this announcement.

REASONS AND BENEFITS FOR ENTERING INTO THE CAPITAL INJECTION AGREEMENT

The Group has extensive experience in the sales and distribution of kitchen appliances in China, with a major focus to improve consumers' health awareness. Over the years, the Group has established an effective offline and online product distribution network comprising distributors, comprising consignment sales, television platforms, online platforms, social media stores and corporate clients.

The Company considers that the health awareness of the consumers in China are rapidly rising and the demand for healthcare products in China is huge. The Company believes that entering into the Capital Injection Agreement is an opportunity for business growth and it can also expand and diversify the Company's customer base. Accordingly, the Board is of the view that entering into the Capital Injection Agreement is in the interests of the Company and its shareholders as a whole.

IMPLICATIONS OF THE LISTING RULES

The Board has reviewed the transaction contemplated under the Capital Injection Agreement and believes that such transaction does not constitute a discloseable transaction of the Company (as defined in Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

GENERAL

The Company will make further announcement(s) on any material development in the above matters where necessary in compliance with the Listing Rules.

By order of the Board
Miji International Holdings Limited
Madam Maeck Can Yue
Chairperson and Executive Director

Hong Kong, 18 July 2022

As at the date of this announcement, the executive Directors of the Company are Madam Maeck Can Yue and Mr. Wu Huizhang; the independent non-executive Directors of the Company are Mr. Wang Shih-fang, Mr. Yan Chi Ming, Mr. Hooi Hing Lee and Mr. Li Wei.

* *For identification purpose only*